Therapeutic potential of target of rapamycin inhibitors. - Wikidata - wikimedia - TriplyDB

Therapeutic potential of target of rapamycin inhibitors.

Therapeutic potential of target of rapamycin inhibitors.

http://www.wikidata.org/entity/Q35976359

about

Local administration of cidofovir for human papilloma virus associated skin lesions in transplant recipients.Conditional transgenesis using Dimerizable Cre (DiCre)An activator of mTOR inhibits oxLDL-induced autophagy and apoptosis in vascular endothelial cells and restricts atherosclerosis in apolipoprotein E⁻/⁻ mice.CXCR6 induces prostate cancer progression by the AKT/mammalian target of rapamycin signaling pathway.Reduced mortality and moderate alcohol consumption: the phospholipase D-mTOR connection FK506 biosynthesis is regulated by two positive regulatory elements in Streptomyces tsukubaensis Autophagy in the control and pathogenesis of viral infection.High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1.Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors The phosphoinositide 3-kinase signalling pathway as a therapeutic target in squamous cell carcinoma of the head and neck.Childhood acute lymphoblastic leukaemia and relapse.New strategies for cardiovascular gene therapy: regulatable pre-emptive expression of pro-angiogenic and antioxidant genes The Enigma of Rapamycin Dosage.Inhibition of S6 kinase suppresses the apoptotic effect of eIF4E ablation by inducing TGF-β-dependent G1 cell cycle arrest.EGFR Inhibition in the Treatment of Non-Small Cell Lung Cancer Translating nociceptor sensitivity: the role of axonal protein synthesis in nociceptor physiology.Key factors in mTOR regulation.Profiling of phospho-AKT, phospho-mTOR, phospho-MAPK and EGFR in non-small cell lung cancer.Clinical trial end points for assessing efficacy of novel therapies for soft-tissue sarcomas.mTOR inhibitors: changing landscape of endocrine-resistant breast cancer.Constitutive activation of mTOR signaling pathway in post-transplant lymphoproliferative disorders.A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma.Origin of the allyl group in FK506 biosynthesis.Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells.Effects of stimulation of autophagy on the urinary excretion of biomarkers of the oxidative status.

P2860

Q33273039-AD0830DA-3F02-49EC-A1A5-281E049E3782 Q33312374-F87AAF7E-D0B5-4EAD-9DDA-5CD80FC569C3 Q33827198-74DD1EA5-864E-4C8E-AC7C-BF011A033AF6 Q33909085-FDBE116A-49D7-41E4-9F8C-BEFFC0F10E8D Q34213257-09E98E22-0C6D-4953-ACC9-A290D1940391 Q34452917-882F074C-745E-407E-A775-AC3E2FF5E9D2 Q35210285-EE543F04-CA08-4B28-9D2F-B109A72646AB Q35694634-E9936808-CDFB-4975-BFFC-F28A0A83BFFE Q36009618-E7767ADE-5ECB-4B8B-A272-13910535DB6E Q36219713-2CFB46AD-8E62-44C0-9A45-5C785264076E Q36340652-DFECD670-2B47-4B78-9120-33304A387B32 Q36385632-6DB8374A-BF55-4D68-A717-7FB575F4BF88 Q36664900-A9D9F162-1700-4C02-9A1A-9822A91639DB Q36806862-B797832C-035A-43F5-91A6-B4EF74C20C40 Q37240726-33FF278E-1902-470F-B643-72044C6D2322 Q37505177-EF6DAFE9-C3CD-45F1-AC13-163DC063636D Q37613506-1064587A-3F5B-4B29-A0AB-987F9920A2F5 Q37733727-4F1E7219-73C8-4CA1-A8F2-0284E4622F53 Q38055499-696F30EF-4E0D-47AD-9A54-EB92CF73FF4F Q38190114-D1A49794-95BD-421A-886C-F2D69D5B97BF Q40213973-39138449-FAF6-44F8-A15B-DFF82C67812D Q40280414-FA5DB1E5-1EF4-4E82-A127-E7E43CE66F90 Q40320365-31243BEC-454E-4230-86D0-8AB4067507B5 Q46727246-07A5E408-0C97-4C22-AEE1-CAFD8C600566 Q46783933-046BE355-653A-4347-84C4-FC2F052299F5

P2860

Therapeutic potential of target of rapamycin inhibitors.

http://www.wikidata.org/entity/Q35976359

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

2004年论文

@zh

2004年论文

@zh-cn

name

Therapeutic potential of target of rapamycin inhibitors.

@ast

Therapeutic potential of target of rapamycin inhibitors.

@en

type

label

Therapeutic potential of target of rapamycin inhibitors.

@ast

Therapeutic potential of target of rapamycin inhibitors.

@en

prefLabel

Therapeutic potential of target of rapamycin inhibitors.

@ast

Therapeutic potential of target of rapamycin inhibitors.

@en

P1433

Q35976359-8E1A13FB-F10A-42DD-B710-97FEBA387724

P1476

Q35976359-9D9CA93D-1C22-4AA5-A116-EB020592B6B4

P2093

Q35976359-A79ED2B0-0F7A-4664-B029-35503C371D63

Q35976359-DC24EE14-7902-405E-BAA8-83969E32E2A2

P2860

Q35976359-01514EEE-020F-4395-A5FA-B4B1F5035752

Q35976359-0228A8BB-D173-4B44-9D73-FEAF117F125B

Q35976359-047E1390-BBB2-4314-A160-E64195BA85C6

Q35976359-04E82B6C-6645-4970-B6A5-E280CA6F361E

Q35976359-05784228-BCF7-46EE-9992-6F57B3C52CF1

Q35976359-06505036-77C1-47D1-895A-692575E692DA

Q35976359-0CFA420F-28B1-4EF5-9767-5129E105EB9E

Q35976359-190E8BC5-66B3-4289-9D10-FF52A6D00C37

Q35976359-1C000DF5-60F8-48AE-8749-C2C9C9D5E002

Q35976359-1EAA71FA-E803-413E-AA68-0AE9995FC7A1

P304

Q35976359-C2C24B9D-A259-4C4A-BCBB-D3B1FF79BC16

P31

Q35976359-AA2FDFAD-99BB-4F56-9FBF-FBCA5CA34E9A

P356

Q35976359-F89F8160-4D5D-43E1-A65D-E272DCD2655B

P407

Q35976359-23A0BDDD-14B2-4723-99AD-14EBF5B1D26B

P433

Q35976359-117A803D-5A8A-4B5A-A3B1-A6776FD3B260

P478

Q35976359-04A9E2D7-96E7-4570-9827-7503E1EB46FF

P577

Q35976359-15F4FD85-3E81-49E9-8DFD-9BDBBF67F9BF

P698

Q35976359-4802CCC7-5CB6-4776-A3D5-C07D7EC94453

P356

14728222.8.6.551

P1433

Expert Opinion on Therapeutic Targets

P1476

Therapeutic potential of target of rapamycin inhibitors.

@en

P2093

John B Easton

http://www.w3.org/2001/XMLSchema#string

Peter J Houghton

http://www.w3.org/2001/XMLSchema#string

P2860

AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas

mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E

Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action

Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5'-cap function

Phosphorylation of eucaryotic translation initiation factor 4B Ser422 is modulated by S6 kinases

A novel mTOR-regulated phosphorylation site in elongation factor 2 kinase modulates the activity of the kinase and its binding to calmodulin

S6K1(-/-)/S6K2(-/-) mice exhibit perinatal lethality and rapamycin-sensitive 5'-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway

Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling

RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1

Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase

P304

551-564

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14728222.8.6.551

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2004-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15584862

http://www.w3.org/2001/XMLSchema#string